| Dokumendiregister | Ravimiamet |
| Viit | REP-1/1199-1 |
| Registreeritud | 05.03.2025 |
| Sünkroonitud | 06.03.2025 |
| Liik | Sissetulev kiri |
| Funktsioon | REP Euroopa Farmakopöaga seotud asjaajamine |
| Sari | REP-1 Euroopa Farmakopöa alane kirjavahetus |
| Toimik | REP-1/2025 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | European Directorate for the Quality of Medicines & HealthCare |
| Saabumis/saatmisviis | European Directorate for the Quality of Medicines & HealthCare |
| Vastutaja | Signe Leito (RA, Peadirektori asetäitja valdkond, Labor) |
| Originaal | Ava uues aknas |
1
Signe Leito
Saatja: [email protected] Saatmisaeg: teisipäev, 18. veebruar 2025 12:17 Adressaat: Signe Leito Teema: Survey: proposed addition of a new monograph on Mifepristone to the Ph. Eur. work programme: EDQM-2025-00745-mail
Please make sure to include in any reply our mail reference: EDQM-2025-00745-mail **************************************************************************** For the attention of NPAs Copy: Presidium Dear Colleagues, Please find below the link to a survey being carried out concerning the proposed addition of the monograph on Mifepristone to the work programme of Group 10C.
In order to have access to the survey, please copy and paste this link into your Internet browser: https://survey.edqm.eu/index.php?r=survey/index&sid=832957&lang=en Deadline for replies: 13 March 2025. Thank you. With kind regards On behalf of Sylvina Iossiphova ___ Villy Nikolova Administrative Support Assistant European Pharmacopoeia Department EDQM Council of Europe Tel.: +33 (0)3 90 21 64 63 / Fax: +33 (0)3 88 41 27 71 https://www.edqm.eu / https://www.edqm.eu/store
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
2
Stay connected with the EDQM **************************************************************************** Please make sure to include in any reply our mail reference: EDQM-2025-00745-mail